OPEN Research Support
head

Consultant, Associate professor
Tine Schytte
Onkologisk Afdeling R, OUH


Projekt styring
Projekt status    Open
 
Data indsamlingsdatoer
Start 01.11.2020  
Slut 31.12.2025  
 



MOMENTUM The Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac study

Short summary

This is a multi-center observational study. Clinical data is of demographic nature (gender, age, tumor type, treatment, side-effects, response, and patient reported outcome. Technical data is MR-scan obtained before, during, and after radiotherapy course. With these data it will hopefully be possible to evaluate tumor response and side-effects. Hopefully the data will be a basis for a number of studies that will be able to clarify the clinical potential of MR-acc treatments.


Rationale

The purpose of the MOMENTUM study is to collect clinical and technical data from all patients treated with radiotherapy on a MR accelerator.

Clinical data is of demographic nature (gender, age, tumor type, treatment, side-effects, response, and patient reported outcome.

Technical data is MR-scan obtained before, during, and after radiotherapy course. With these data it will hopefully be possible to evaluate tumor response and side-effects. Hopefully the data will be a basis for a number of studies that will be able to clarify the clinical potential of MR-acc treatments. Part of this evolution could be to find a method to make the medical images even better than the current quality.

The study is an observational study.


Description of the cohort

Patients referred for radiotherapy on MR accelerator for various cancer types will be offered inclusion in the study.


Data and biological material

Clinical data is of demographic nature (gender, age, tumor type, treatment, side-effects, response, and patient reported outcome.

Technical data is MR-scan obtained before, during, and after radiotherapy course.


Collaborating researchers and departments

University Medical Center, Utrecht, NL; Nedelands Kanker Instituut, Amsterdam, NL; The Christie NHS Foundation Trust, Manchester, UK; The Royal Marsden NHS Foundation Trust, London, UK; The University of Texas M.D.Anderson Cancer Center, Houston, Texas, US; The Medical College of Wisconsin, Milwaukee, Wisconsin, US; Sunnybrook Research Institute, Toronto, CAN; ELEKTA Limited AB, Stockholm, Sweden